Paul Martin

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action <i>in vivo</i> , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Barry R. Davies, Armelle Logié, Jennifer S. McKay et al. · Molecular Cancer Therapeutics · 2007 · 389 citations

Medicine, Oncology, Pharmacology +17

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

Paul Martin, Mike J. Warwick, Aaron Dane et al. · Clinical Therapeutics · 2003 · 286 citations

Pharmacy, Pharmacokinetics, Pharmacology +7

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers

Paul Martin · Clinical Therapeutics · 2003 · 190 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +11

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Paul Martin, Patrick Mitchell, Dennis W. Schneck · British Journal of Clinical Pharmacology · 2002 · 150 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

The effect of fluconazole on the pharmacokinetics of rosuvastatin

Kevin D. Cooper, Paul Martin, Aaron Dane et al. · European Journal of Clinical Pharmacology · 2002 · 113 citations

Pharmacy, Pharmacokinetics, Pharmacology +5